Slingshot Insights | Catalyst

Catalyst

Slingshot members are tracking this event:

Boehringer Ingelheim Announces Phase 3 Results for Humira Biosimilar Candidate in Active Rheumatoid Arthritis

Source Link:: http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2016/10-26-2016-boehringer-ingelheims-adalimumab-biosimilar-candidate-shows-similar-efficacy-safety-profile-humira-pivotal-phase-iii-study.html

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

Boehringer Ingelheim

100%

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Oct 26, 2016

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Active Rheumatoid Arthritis, Humira, Biosimilar, Phase 3, Results